Page 141 - 《中国药房》2026年2期

[11] 李爽，刘静飞，陈阳，等 . 1 型糖尿病医源性高胰岛素血 vanced hybrid closed-loop system：a randomised con‐
症致胰岛素抵抗的研究进展[J]. 中华内分泌代谢杂志， trolled trial[J]. Diabetologia，2024，67（12）：2637-2649.
2024，40（9）：811-816. [23] ELKABBANY Z A，ABDEL RAHMAN ISMAIL E，
[12] POH SHEAN W，CHIN VOON T，BIN LONG BIDIN M HAMED E T，et al. The impact of vildagliptin as an add-
B，et al. Effects of metformin on glycaemic variability in on therapy on matrix metalloproteinase-14 levels，liver
combination with insulin in overweight/obese patients stiffness and subclinical atherosclerosis in adolescents
with type 1 diabetes[J]. J R Coll Physicians Edinb，2023， with type 1 diabetes and non-alcoholic steatohepatitis：a
53（2）：94-103. randomized controlled trial[J]. Diabetes Obes Metab，
[13] SHEIKHY A，EYDIAN Z，FALLAHZADEH A，et al. 2024，26（12）：5857-5869.
Benefits of metformin add-on insulin therapy（MAIT） for [24] YAN X，LI X，LIU B W，et al. Combination therapy with
HbA1C and lipid profile in adolescents with type 1 diabetes saxagliptin and vitamin D for the preservation of β -cell
mellitus：preliminary report from a double-blinded， function in adult-onset type 1 diabetes：a multi-center，ran‐
placebo-controlled，randomized clinical trial[J]. J Pediatr domized，controlled trial[J]. Signal Transduct Target Ther，
Endocrinol Metab，2022，35（4）：505-510. 2023，8（1）：158.
[14] ELBARBARY N S，ABDEL RAHMAN ISMAIL E， [25] 张娇娇，刘以安，方翼 . 治疗 2 型糖尿病药物：考格列汀
GHALLAB M A. Effect of metformin as an add-on [J]. 临床药物治疗杂志，2025，23（2）：27-31.
therapy on neuregulin-4 levels and vascular-related com‐ [26] DELRUE C，SPEECKAERT M M. Mechanistic pathways
plications in adolescents with type 1 diabetes：a rando- and clinical implications of GLP-1 receptor agonists in
mized controlled trial[J]. Diabetes Res Clin Pract，2022， type 1 diabetes management[J]. Int J Mol Sci，2024，25
186：109857. （17）：9351.
[15] ANSON M，ZHAO S S，AUSTIN P，et al. SGLT2i and [27] SHENKER M N，SHALITIN S. Use of GLP-1 receptor
GLP-1 RA therapy in type 1 diabetes and reno-vascular agonists for the management of type 1 diabetes：a pedia-
outcomes：a real-world study[J]. Diabetologia，2023，66 tric perspective[J]. Horm Res Paediatr，2025，98（4）：
（10）：1869-1881. 405-424.
[16] GARCIA-TIRADO J，FARHY L，NASS R，et al. Auto‐ [28] KOBAYATI A，HAIDAR A，TSOUKAS M A. Glucagon-
mated insulin delivery with SGLT2i combination therapy like peptide-1 receptor agonists as adjunctive treatment
in type 1 diabetes[J]. Diabetes Technol Ther，2022，24（7）： for type 1 diabetes：renewed opportunities through tailored
461-470. approaches? [J]. Diabetes Obes Metab，2022，24（5）：
[17] BOEDER S，DAVIES M J，MCGILL J B，et al. Beta- 769-787.
hydroxybutyrate levels and risk of diabetic ketoacidosis in [29] SHAH V N，AGESEN R M，BARDTRUM L，et al. Deter‐
adults with type 1 diabetes treated with sotagliflozin[J]. minants of liraglutide treatment discontinuation in type 1
Diabetes Technol Ther，2024，26（9）：618-625. diabetes：a post hoc analysis of adjunct one and adjunct
[18] PETERSEN M C，JONES K E，MARKOV A M，et al. Ef‐ two randomized placebo-controlled clinical studies[J]. J
fect of dapagliflozin on blood and breath ketones during Diabetes Sci Technol，2025，19（2）：321-331.
supervised insulin withdrawal in adults with type 1 diabe‐ [30] ZENZ S，REGITTNIG W，BOULGAROPOULOS B，et
tes：a randomized crossover trial[J]. Diabetes Obes Metab， al. Effect of liraglutide treatment on whole-body glucose
2025，27（6）：3124-3131. fluxes in C-peptide-positive type 1 diabetes during hypo‐
[19] BOEDER S C，THOMAS R L，LE ROUX M J，et al. glycemia[J]. J Clin Endocrinol Metab，2022，107（9）：
Combination SGLT2 inhibitor and glucagon receptor an‐ e3583-e3593.
tagonist therapy in type 1 diabetes：a randomized clinical [31] AKTURK H K，DONG F，SNELL-BERGEON J K，et al.
trial[J]. Diabetes Care，2025，48（1）：52-60. Efficacy and safety of tirzepatide in adults with type 1 dia‐
[20] WANG Q X，LONG M，QU H，et al. DPP-4 inhibitors as betes：a proof of concept observational study[J]. J Diabe‐
treatments for type 1 diabetes mellitus：a systematic re‐ tes Sci Technol，2025，19（2）：292-296.
view and meta-analysis[J]. J Diabetes Res，2018，2018： [32] LEE M M Y，GHOURI N，MISRA A，et al. Comparative
5308582. efficacy of glucagon-like peptide 1 receptor agonists for
[21] DAVIS H，JONES BRISCOE V，DUMBADZE S，et al. cardiovascular outcomes in Asian versus white popula‐
Using DPP-4 inhibitors to modulate beta cell function in tions：systematic review and meta-analysis of randomized
type 1 diabetes and in the treatment of diabetic kidney di- trials of populations with or without type 2 diabetes and/or
sease[J]. Expert Opin Investig Drugs，2019，28（4）： overweight or obesity[J]. Diabetes Care，2025，48（3）：
377-388. 489-493.
[22] ELBARBARY N S，ISMAIL E A，EL-HAMAMSY M H， [33] 严婕妮，陈阳，杨涛. 1型糖尿病的非胰岛素辅助降糖治
et al. The DPP-4 inhibitor sitagliptin improves glycaemic 疗[J]. 中国实用内科杂志，2020，40（1）：11-18.
control and early-stage diabetic nephropathy in adoles‐ （收稿日期：2025-07-10 修回日期：2025-12-31）
cents with type 1 diabetes using the MiniMed 780G ad‐ （编辑：胡晓霖）

中国药房 2026年第37卷第2期 China Pharmacy 2026 Vol. 37 No. 2 · 267 ·